Tags |
|
|
Links |
|
|
Digg It - It’s Official; We Are Now A Bankrupt Society?
The Government’s Insolvency Service claimed that 27,644 people were either made bankrupt or entered
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
into an Individual Voluntary Arrangement (IVA) as a way to control or manage their debts in an order
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
ed fashion.
It was too early obviously to know how big a percentage of those who entered into an IV
It was too early obviously to know how big a percentage of those who entered into an IV
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
A had it failed by their manager or supervisor but it has been claimed previously that in some cases
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
up to 50/60 percent of those entering an IVA fail to complete it in an orderly manner and therefore
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
find themselves being made forcibly bankrupt at a later date.
The other key statistic was that inso
The other key statistic was that inso
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
lvencies were apparently 55% higher than during the comparable period this time last year and the sm
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
art money (to spoil the metaphor) is on the figure topping the 100,000 mark for the year.
It would
It would
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
ppear that the proportion of those applying for and entering IVA’s rose as compared to those decidin
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
g (or having decided for them) to go down the straight bankruptcy route. This latter fact has been h
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
eavily criticised (and understandably so) by the mainstream press as th e process of an IVA or (Chap
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
ter 13 Bankruptcy, its equivalent in the US) is very heavily marketed as the ultimate solution to pr
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
vide the “maintenance of the maximum amount of dignity in an otherwise sordid scenario”.
This is no
This is no
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
t entirely the case and is most certainly not always true. Whilst the principle of an IVA is fine an
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
d extremely noble, sometimes it is just not practical and therefore should be counselled against at
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
the earliest opportunity. That is not to say that IVA’s are a totally worthless idea in principle.
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
n the right circumstances they are ideal and managed correctly work extremely well for those who ent
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
er into the process with their eyes firmly open. Sadly this is not always the case and most often th
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
e reality is the exact opposite.
In part two of this article we will be taking a look in some detai
In part two of this article we will be taking a look in some detai
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
l at the right way and conversely the wrong way about entering into and managing successfully an IVA
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.diggit.org.ua/article/90925/diggit-Its-Official-We-Are-Now-A-Bankrupt-Society.html">It’s Official; We Are Now A Bankrupt Society?</a>
BB link (for phorums):
[url=http://www.diggit.org.ua/article/90925/diggit-Its-Official-We-Are-Now-A-Bankrupt-Society.html]It’s Official; We Are Now A Bankrupt Society?[/url]
Related Articles:
Web Conference Services - Outsourcing Your Conferencing Needs
Powerful Nonprofit Blogging via The Corporate Blogging Book
The Secrets of Using Internet Marketing to Expand Your Clientele
Bookmark it:
|